Prostasin, a potential tumor marker in ovarian cancer: a pilot study
AUTOR(ES)
Costa, Fernanda Pires, Batista Junior, Eraldo Luis, Zelmanowicz, Alice, Svedman, Christer, Devenz, Gabriela, Alves, Silvana, Silva, Andrea Simões Martins da, Garicochea, Bernardo
FONTE
Clinics
DATA DE PUBLICAÇÃO
2009
RESUMO
INTRODUCTION: Ovarian cancer is generally diagnosed at advanced stages of the disease; therefore, poor prognoses are typical. The development of tumor markers is thus of utmost importance. Prostasin is a protease that in normal tissues is highly expressed only in the prostate gland and seminal fluid. A previous study showed that prostasin is highly overexpressed in ovarian cancer cell lines. This study sought to evaluate the expression of prostasin in ovarian cancer. METHODS: Fresh tumor samples of ovarian epithelial cancer (n: 12) were analyzed for expression of prostasin mRNA (messenger ribonucleic acid) by conventional and real time quantitative PCR (polymerase chain reaction). As a standard control, a normal prostate sample was analyzed. RESULTS: Using conventional PCR, prostasin was detected in all but one sample. Using quantitative PCR, prostasin was over-expressed in all but one of the samples as compared to the control (prostate). CONCLUSIONS: These findings indicate that prostasin is overexpressed in many epithelial ovarian cancers. Further studies of prostasin as a potential biomarker for this disease are warranted.
Documentos Relacionados
- An Ovarian Cancer Tumor Marker, CA 125, Comes of Age
- Communication about sexual problems and sexual concerns in ovarian cancer: qualitative study
- Secondary healing strategy for difficult wound closure in invasive vulvar cancer: a pilot case-control study
- Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression.
- Chemoresistance in human ovarian cancer: the role of apoptotic regulators